This study also corroborates evidence for individual candidate biomarkers of high-risk IPMN, including CD55, laminin subunit gamma 2 (LAMC2), amphiregulin (AREG), and others. This evidence concerns the gene AREG and pancreatic intraductal papillary-mucinous neoplasm.